Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

<p>Abstract</p> <p>Background</p> <p>Anthracyclines and taxanes are commonly used in the treatment of breast cancer. However, tumor resistance to these drugs often develops, possibly due to overexpression of drug transporters. It remains unclear whether drug resistance...

Full description

Bibliographic Details
Main Authors: Veitch Zachary, Guo Baoqing, Villeneuve David J, Laberge Monique L, Hembruff Stacey L, Cecchetto Melanie, Parissenti Amadeo M
Format: Article
Language:English
Published: BMC 2008-11-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/8/318
id doaj-12dadf9093bf40e5b03ab2dcc5a67bf4
record_format Article
spelling doaj-12dadf9093bf40e5b03ab2dcc5a67bf42020-11-24T21:19:08ZengBMCBMC Cancer1471-24072008-11-018131810.1186/1471-2407-8-318Role of drug transporters and drug accumulation in the temporal acquisition of drug resistanceVeitch ZacharyGuo BaoqingVilleneuve David JLaberge Monique LHembruff Stacey LCecchetto MelanieParissenti Amadeo M<p>Abstract</p> <p>Background</p> <p>Anthracyclines and taxanes are commonly used in the treatment of breast cancer. However, tumor resistance to these drugs often develops, possibly due to overexpression of drug transporters. It remains unclear whether drug resistance <it>in vitro </it>occurs at clinically relevant doses of chemotherapy drugs and whether both the onset and magnitude of drug resistance can be temporally and causally correlated with the enhanced expression and activity of specific drug transporters. To address these issues, MCF-7 cells were selected for survival in increasing concentrations of doxorubicin (MCF-7<sub>DOX-2</sub>), epirubicin (MCF-7<sub>EPI</sub>), paclitaxel (MCF-7<sub>TAX-2</sub>), or docetaxel (MCF-7<sub>TXT</sub>). During selection cells were assessed for drug sensitivity, drug uptake, and the expression of various drug transporters.</p> <p>Results</p> <p>In all cases, resistance was only achieved when selection reached a specific threshold dose, which was well within the clinical range. A reduction in drug uptake was temporally correlated with the acquisition of drug resistance for all cell lines, but further increases in drug resistance at doses above threshold were unrelated to changes in cellular drug uptake. Elevated expression of one or more drug transporters was seen at or above the threshold dose, but the identity, number, and temporal pattern of drug transporter induction varied with the drug used as selection agent. The pan drug transporter inhibitor cyclosporin A was able to partially or completely restore drug accumulation in the drug-resistant cell lines, but had only partial to no effect on drug sensitivity. The inability of cyclosporin A to restore drug sensitivity suggests the presence of additional mechanisms of drug resistance.</p> <p>Conclusion</p> <p>This study indicates that drug resistance is achieved in breast tumour cells only upon exposure to concentrations of drug at or above a specific selection dose. While changes in drug accumulation and the expression of drug transporters does occur at the threshold dose, the magnitude of resistance cannot be attributed solely to changes in drug accumulation or the activity of drug transporters. The identities of these additional drug-transporter-independent mechanisms are discussed, including their likely clinical relevance.</p> http://www.biomedcentral.com/1471-2407/8/318
collection DOAJ
language English
format Article
sources DOAJ
author Veitch Zachary
Guo Baoqing
Villeneuve David J
Laberge Monique L
Hembruff Stacey L
Cecchetto Melanie
Parissenti Amadeo M
spellingShingle Veitch Zachary
Guo Baoqing
Villeneuve David J
Laberge Monique L
Hembruff Stacey L
Cecchetto Melanie
Parissenti Amadeo M
Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
BMC Cancer
author_facet Veitch Zachary
Guo Baoqing
Villeneuve David J
Laberge Monique L
Hembruff Stacey L
Cecchetto Melanie
Parissenti Amadeo M
author_sort Veitch Zachary
title Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
title_short Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
title_full Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
title_fullStr Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
title_full_unstemmed Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
title_sort role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2008-11-01
description <p>Abstract</p> <p>Background</p> <p>Anthracyclines and taxanes are commonly used in the treatment of breast cancer. However, tumor resistance to these drugs often develops, possibly due to overexpression of drug transporters. It remains unclear whether drug resistance <it>in vitro </it>occurs at clinically relevant doses of chemotherapy drugs and whether both the onset and magnitude of drug resistance can be temporally and causally correlated with the enhanced expression and activity of specific drug transporters. To address these issues, MCF-7 cells were selected for survival in increasing concentrations of doxorubicin (MCF-7<sub>DOX-2</sub>), epirubicin (MCF-7<sub>EPI</sub>), paclitaxel (MCF-7<sub>TAX-2</sub>), or docetaxel (MCF-7<sub>TXT</sub>). During selection cells were assessed for drug sensitivity, drug uptake, and the expression of various drug transporters.</p> <p>Results</p> <p>In all cases, resistance was only achieved when selection reached a specific threshold dose, which was well within the clinical range. A reduction in drug uptake was temporally correlated with the acquisition of drug resistance for all cell lines, but further increases in drug resistance at doses above threshold were unrelated to changes in cellular drug uptake. Elevated expression of one or more drug transporters was seen at or above the threshold dose, but the identity, number, and temporal pattern of drug transporter induction varied with the drug used as selection agent. The pan drug transporter inhibitor cyclosporin A was able to partially or completely restore drug accumulation in the drug-resistant cell lines, but had only partial to no effect on drug sensitivity. The inability of cyclosporin A to restore drug sensitivity suggests the presence of additional mechanisms of drug resistance.</p> <p>Conclusion</p> <p>This study indicates that drug resistance is achieved in breast tumour cells only upon exposure to concentrations of drug at or above a specific selection dose. While changes in drug accumulation and the expression of drug transporters does occur at the threshold dose, the magnitude of resistance cannot be attributed solely to changes in drug accumulation or the activity of drug transporters. The identities of these additional drug-transporter-independent mechanisms are discussed, including their likely clinical relevance.</p>
url http://www.biomedcentral.com/1471-2407/8/318
work_keys_str_mv AT veitchzachary roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
AT guobaoqing roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
AT villeneuvedavidj roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
AT labergemoniquel roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
AT hembruffstaceyl roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
AT cecchettomelanie roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
AT parissentiamadeom roleofdrugtransportersanddrugaccumulationinthetemporalacquisitionofdrugresistance
_version_ 1726006889430384640